1582 - Real-World Use of Long-Acting Cabotegravir + Rilpivirine in the US: Effectiveness in the First Year

Friday, October 21, 2022

3:15 PM – 3:30 PM US ET

Location: 206

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Presenting Author(s)

Michael G. Sension, MD

Medical Director
can community health
Miami Beach, FL, United States

Disclosure: Disclosure(s): Gilead: Advisor/Consultant (), Honoraria (); Viiv: Advisor/Consultant (), Grant/Research Support (), Honoraria ()

Slides

Co-Author(s)

Ricky K. Hsu, MD (he/him/his)

National Medical Director of Clinical Standards, Policy, & Education\ Associate Professor of Medicine
AIDS Healthcare Foundation\ NYU School of Medicine
New York, New York, United States

Disclosure: Disclosure(s): Gilead: Honoraria (); Merck: Honoraria (); ViiV: Advisor/Consultant (), Grant/Research Support (), Honoraria ()
Jennifer S. Fusco, BS

Chief Science Officer
Epividian, Inc.
Durham, North Carolina, United States

Disclosure: Disclosure(s): AIDS Healthcare Foundation: Client of my employer (); EMD Serono: Client of my employer (); Gilead Sciences: Client of my employer (); Janssen: Client of my employer (); Merck & Co.: Client of my employer (); TheraTechnologies: Client of my employer (); ViiV Healthcare: Client of my employer ()
LB

Laurence Brunet, PhD

Director of Epidemiology
Epividian, Inc.
Durham, North Carolina, United States

Disclosure: Disclosure(s): AIDS Healthcare Foundation: Client of my employer (); EMD Serono: Client of my employer (); Gilead Sciences: Client of my employer (); Janssen: Client of my employer (); Merck & Co: Client of my employer (); TheraTechnologies: Client of my employer (); ViiV Healthcare: Client of my employer ()
QC

Quateka Cochran, Masters of Nursing

Regional Nursing Director
Aids Healthcare Foundation
Miami Beach, Florida, United States

Disclosure: Disclosure(s): No financial relationships to disclose
CU

Christine Uranaka, BSN

National Director of Quality
AIDS Healthcare Foundation
Los Angeles, California, United States

Disclosure: Disclosure(s): No financial relationships to disclose
GS

Gayathri Sridhar, MBBS, MPH, PhD

Director
ViiV Healthcare
Fairfax, Virginia, United States

Disclosure: Disclosure(s): GlaxoSmithKline: Stocks/Bonds (); ViiV Healthcare: Employment ()
Vani Vannappagari, MBBS, MPH, PhD

Global Head, Epidemiology & Real World Evidence
ViiV Healthcare
Research Triangle Park, North Carolina, United States

Disclosure: Disclosure(s): ViiV Healthcare: I am full time employee of ViiV Healthcare and receive GlaxoSmithKline stock as part of my compensation package (), Stocks/Bonds ()
AZ

Andrew Zolopa, MD

Head of North America Medical Affairs
ViiV Healthcare
Portola Valley, California, United States

Disclosure: Disclosure(s): ViiV Healthcare: full time employee (), Stocks/Bonds ()
Jv

Jean A. van Wyk, MB,ChB; MFPM

Global Medical Lead, VP
ViiV Healthcare Limited
Brentford, England, United Kingdom

Disclosure: Disclosure(s): ViiV Healthcare Limited: I am an employee of ViiV Healthcare (), Stocks/Bonds ()
LM

Lewis McCurdy, MD

Specialty Director
Atrium Health
Charlotte, North Carolina, United States

Disclosure: Disclosure(s): No financial relationships to disclose
GF

Gregory P. Fusco, MD, MPH

Chief Executive Officer & Chief Medical Officer
Epividian, Inc.
Durham, North Carolina, United States

Disclosure: Disclosure(s): AIDS Healthcare Foundation: Client of employer (); EMD: Grant/Research Support (); Gilead Sciences: Client of employer (); Janssen: Client of employer (); Merck & Co.: Client of employer (); Theratechnologies: Client of employer (); ViiV Healthcare: Client of employer ()
MW

Michael B. Wohlfeiler, JD, MD, AAHIVS

Chief Medical Officer
AIDS Healthcare Foundation
Miami Beach, Florida, United States

Disclosure: Disclosure(s): No financial relationships to disclose

Disclosure(s):

Michael G. Sension, MD: Gilead: Advisor/Consultant (), Honoraria (); Viiv: Advisor/Consultant (), Grant/Research Support (), Honoraria ()

Ricky K. Hsu, MD: Gilead: Honoraria (); Merck: Honoraria (); ViiV: Advisor/Consultant (), Grant/Research Support (), Honoraria ()

Jennifer S. Fusco, BS: AIDS Healthcare Foundation: Client of my employer (); EMD Serono: Client of my employer (); Gilead Sciences: Client of my employer (); Janssen: Client of my employer (); Merck & Co.: Client of my employer (); TheraTechnologies: Client of my employer (); ViiV Healthcare: Client of my employer ()

Laurence Brunet, PhD: AIDS Healthcare Foundation: Client of my employer (); EMD Serono: Client of my employer (); Gilead Sciences: Client of my employer (); Janssen: Client of my employer (); Merck & Co: Client of my employer (); TheraTechnologies: Client of my employer (); ViiV Healthcare: Client of my employer ()

Quateka Cochran, Masters of Nursing: No financial relationships to disclose

Christine Uranaka, BSN: No financial relationships to disclose

Gayathri Sridhar, MBBS, MPH, PhD: GlaxoSmithKline: Stocks/Bonds (); ViiV Healthcare: Employment ()

Vani Vannappagari, MBBS, MPH, PhD: ViiV Healthcare: I am full time employee of ViiV Healthcare and receive GlaxoSmithKline stock as part of my compensation package (), Stocks/Bonds ()

Andrew Zolopa, MD: ViiV Healthcare: full time employee (), Stocks/Bonds ()

Jean A. van Wyk, MB,ChB; MFPM: ViiV Healthcare Limited: I am an employee of ViiV Healthcare (), Stocks/Bonds ()

Lewis McCurdy, MD: No financial relationships to disclose

Gregory P. Fusco, MD, MPH: AIDS Healthcare Foundation: Client of employer (); EMD: Grant/Research Support (); Gilead Sciences: Client of employer (); Janssen: Client of employer (); Merck & Co.: Client of employer (); Theratechnologies: Client of employer (); ViiV Healthcare: Client of employer ()

Michael B. Wohlfeiler, JD, MD, AAHIVS: No financial relationships to disclose